OTC Markets OTCPK - Delayed Quote USD

ALK-Abelló A/S (AKBLF)

22.35

0.00

(0.00%)

At close: January 3 at 3:00:00 PM EST

3 Stocks That May Be Trading Below Estimated Value

In the current climate, global markets are experiencing volatility with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainties, while European and Asian indices also reflect investor apprehension over interest rate outlooks. Amid these fluctuations, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. A good stock in this context is one that...

Simply Wall St. 11 days ago

AKBLF
0.00%
CSCCF
ALK – Financial calendar for the 2025 financial year

2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 29 January 2025 at the latest (may be emailed to investor@alk.net) 8 April 2025: Silent period 6 May 2025: Three-month interim report (Q1)

GlobeNewswire 15 days ago

AKBLF
0.00%
Positive results advance peanut tablet to phase II development

ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK (ALKB:DC / OMX: ALK B) today announced positive interim results from its phase I/II clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the trial, which involve

GlobeNewswire 17 days ago

AKBLF
0.00%
ACARIZAX® approved in Europe for treatment of young children

ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever paediat

GlobeNewswire 23 days ago

AKBLF
0.00%
ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, evaluating the efficacy and safety in children (5-11 years) with house dust mite allergic rhinitis.1 With the acceptance for publication, ALK’s MT-12 phase 3 trial has been evaluated by the journal for its methodology, relevance, and clinical implications. This scrutiny helps ensure that

GlobeNewswire last month

AKBLF
0.00%
Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

Alk-Abello AS (AKBLF) reports robust organic revenue growth and a significant increase in EBIT margin, despite challenges in North America.

GuruFocus.com last month

ALK-B.CO
3 Stocks That May Be Trading At A Discount Of Up To 41.4%

In the current global market environment, uncertainty surrounding the incoming Trump administration's policies has contributed to volatility, with U.S. stocks experiencing a partial reversal of recent gains and sector returns showing significant variation. As investors navigate these fluctuations and consider potential policy impacts on corporate earnings, identifying stocks that may be undervalued can offer opportunities for those seeking value investments. A good stock in this context is...

Simply Wall St. last month

AKBLF
0.00%
GJNSF

GJNSY
Nine-month interim report (Q3) 2024 (unaudited)

Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales and a recovery in Jext® sales. Europe and International markets were key contributors to growth. The operating profit improved in line with ALK’s financial ambitions, and the full-year outlook remains unchanged. Q3 performance highlights Comparative figures for Q3 2023 are shown in brackets. Revenue growth

GlobeNewswire last month

AKBLF
0.00%
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis, in Europe, Canada and other geographies outside of the U.S. ARS Pharma retains all rights to neffy in the U.S., and there are no changes to its existing partnerships in Japan, China, Australia and New Zealand. Published first on TheFly – the ultimat

TipRanks last month

AKBLF
0.00%
SPRY
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, Australia, and China.

Pharmaceutical Technology last month

SPRY

ALK-B.CO

GLDAF
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK’s new strategy Allergy+ and supports ALK’s long-term financial ambitions. Needle-free, nasal delivery of adrenaline has th

GlobeNewswire last month

AKBLF
0.00%
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast T

GlobeNewswire last month

AKBLF
0.00%
Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook

Alk-Abello AS (AKBLF) reports impressive Q2 performance with 21% organic revenue growth and raises full-year guidance amid robust European sales.

GuruFocus.com 2 months ago

ALK-B.CO
ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced the licensing of a new line of ALK branded allergy skin testing devices and well trays. This new line includes the AccuTest-1™, AccuTest-8™ and AccuTest-10™ Allergy Skin Testing Devices for allergy testing and diagnosis as well as the AccuTest™ 48-well and 60-well allergen trays.

PR Newswire 2 months ago

AKBLF
0.00%
Six-month interim report (Q2) 2024

Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales, and improved performance of injection- and drop-based allergy immunotherapy products. ALK’s European and International markets were key contributors to growth. The increase in operating profit (EBIT) of 189% is in-line with ALK’s financial targets. Full-year outlook has been upgraded. Q2 performance

GlobeNewswire 4 months ago

AKBLF
0.00%
ALK upgrades its full-year revenue and earnings outlook

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is now expected to grow by 14-16% in local currencies (prev.: 12-15%).The EBIT margin is now expected to improve to 19-21% (prev.: 18-20%) vs. 14% in 2023. The full-year revenue outlook has been upgraded primarily to reflect the strong sales of tablets and injection- and drop-based allergy immunotherapy pro

GlobeNewswire 4 months ago

AKBLF
0.00%
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting w

GlobeNewswire 4 months ago

AKBLF
0.00%
ALK provides update on regulatory process for the house dust mite allergy tablet in China

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will continue to work with the authorities to obtain regulatory approval of the HDM tablet in China, which may involve establishing additional clinical data in Chinese patients. The delay in the regulatory approval process does not impact ALK’s financial guidance for 2024, or its ability t

GlobeNewswire 6 months ago

AKBLF
0.00%
ALK launches new growth strategy and 2028 financial ambitions

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position in food allergy and anaphylaxis, as well as pursuing new innovations to address adjacent allergic conditions with high unmet needs. The strategy targets average revenue growth of minimum 10% in local currencies (5-year CAGR) until 2

GlobeNewswire 6 months ago

AKBLF
0.00%
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented new data from two paediatric phase 3 clinical trials evaluating SQ sublingual immunotherapy (SLIT) tablets in house dust mite (HDM) and tree pollen respiratory allergy. ALK contributed with a total of 18 scientific abstracts within the EAACI 2024 scientific programme – this included groundbreakin

GlobeNewswire 6 months ago

AKBLF
0.00%

Performance Overview

Return	AKBLF	OMX Copenhagen 25 Index
YTD	0.00%	+1.64%
1-Year	+68.68%	-0.94%
3-Year	-12.70%	-8.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ALK-Abelló A/S (AKBLF)

3 Stocks That May Be Trading Below Estimated Value

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

3 Stocks That May Be Trading At A Discount Of Up To 41.4%

Nine-month interim report (Q3) 2024 (unaudited)

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook

ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

Six-month interim report (Q2) 2024

ALK upgrades its full-year revenue and earnings outlook

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

ALK provides update on regulatory process for the house dust mite allergy tablet in China

ALK launches new growth strategy and 2028 financial ambitions

ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies

Performance Overview